問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

林淳榮
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林淳榮

List

8Cases

2016-02-01 - 2017-09-14

Phase II/III

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    GS-5745

Participate Sites
6Sites

Terminated5Sites

2017-03-01 - 2019-09-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically confirmed Duodenal Ulcer Subjects with or without Helicobacter pylori infection

  • Condition/Disease

    Duodenal Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Terminated5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-03-01 - 2020-06-30

Phase III

A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection

  • Condition/Disease

    Gastric Ulcer

  • Test Drug

    TAK-438

Participate Sites
6Sites

Recruiting5Sites

邱正堂
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-08-17 - 2017-11-30

Phase III

A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily administration of TAK-438 20 mg compared to Lansoprazole 30 mg in the Treatment of Subjects with Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

侯明志
Taipei Veterans General Hospital

Digestive System Department

2015-08-17 - 2018-02-28

Phase III

A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis

  • Condition/Disease

    Erosive Esophagitis

  • Test Drug

    TAK-438

Participate Sites
14Sites

Terminated12Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

吳登強
Kaohsiung Municipal Gangshan Hospital

未分科

2009-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-03-01 - 2016-06-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase III Trial Of TSU-68 In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    TSU-68

Participate Sites
14Sites

Terminated14Sites

2016-07-21 - 2018-11-03

Phase II

A PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

  • Condition/Disease

    ulcerative colitis

  • Test Drug

    PF-06480605

Participate Sites
4Sites

Terminated3Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB